Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DVC1 0101

Next Previous
X
Search
Drug Profile

DVC1 0101

Alternative Names: Angiogenic-gene-therapy-ID-Pharma; BF-30; DVC1-0101; Fibroblast growth factor 2 gene therapy - ID Pharma; Recombinant SeV-hFGF2/dF; SeV-10101; SeV-hFGF2/dF; SEV1-0101

Latest Information Update: 28 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator DNAVEC Corporation
  • Developer ID Pharma; Kyushu University; Shenzhen Salubris Pharmaceuticals
  • Class Anti-ischaemics; Gene therapies; Nucleic acids; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Fibroblast growth factor replacements; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Intermittent claudication; Peripheral ischaemia
  • No development reported Peripheral arterial occlusive disorders

Most Recent Events

  • 28 Apr 2023 No recent reports of development identified for phase-I development in Peripheral-arterial-occlusive-disorders in China (IM, Injection)
  • 16 Apr 2021 Phase-I/II development is ongoing in Australia for Intermittent claudication and Peripheral ischaemia (IM) (ACTRN12615001144505)
  • 05 Sep 2018 Phase-I clinical trials in Peripheral arterial occlusive disorders in China (IM) (NCT03668353)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top